

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/8778090>

The TUBEX typhoid test detects current Salmonella infections

Article in *Journal of Immunological Methods* · March 2004

DOI: 10.1016/j.jim.2003.10.020 · Source: PubMed

CITATIONS

4

READS

187

5 authors, including:



[Wojciech Feleszko](#)

Medical University of Warsaw

69 PUBLICATIONS 1,222 CITATIONS

[SEE PROFILE](#)

Some of the authors of this publication are also working on these related projects:



Contact allergens in topical corticosteroid vehicles [View project](#)

Rapid Diagnosis of Acute *Salmonella* Gastrointestinal Infection

Grzegorz Oracz,^{1,ab} Wojciech Feleszko,^{1,b} Dorota Golicka,³
Joanna Maksymiuk,³ Agnieszka Klonowska,¹ and Hanna Szajewska²

Departments of ¹Pediatric Pneumonology, Allergy, and Hematology and ²Pediatric Gastroenterology and Nutrition, ³Medical University of Warsaw, Warsaw, Poland

Serologic tests for the detection of *Salmonella* serotype Enteritidis in children may become supplementary to stool culture examination. A total of 190 children were examined with a new 1-step, 2-minute test (TUBEX) that detects anti-*Salmonella* immunoglobulin M antibodies, which was found to be 92.6% sensitive and 94.8% specific ($P < .0001$).

Acute infectious diarrhea is a common disease in childhood, and *Salmonella* is the most likely bacterial causes in children in industrialized countries [1, 2]. The reported incidence of salmonellosis has increased during the past 50 years in the United States and remains an important cause of diarrheal illness, causing ~1.4 million episodes and 600 deaths annually [3, 4]. Food-borne, non-Typhi serotypes, mainly group D *Salmonella* (*Salmonella enterica* subspecies *enterica* serotype Enteritidis) predominate among the most common *Salmonella* serotypes, with the highest incidence rates among infants aged <1 year and a definitely high frequency among children aged <9 years [2]. The dominance of only few serotypes is more pronounced in the European countries. For example, in Poland in 1999, the most frequent serotype, *Salmonella* serotype Enteritidis, was identified in ~92% of 23,000 cases [5], thus remaining a leading cause of bacterial infectious diarrhea. Salmonellosis in older children and adults is usually a self-limited disease (presenting as acute gastroenteritis), and therapy should

mainly be directed at preventing dehydration [1, 6]. However, it is justified to use antimicrobial therapy in infants aged ≤ 3 months with *Salmonella* gastroenteritis, as well as in immunocompromised patients and patients with septicemia [1, 6, 7]. In these patients, antibiotic treatment will be the most successful in the early stages of illness, and delaying treatment may result in septicemia-related dehydration and renal failure. Because the early stage is often clinically difficult to determine (because stool and blood culture results are generally available in ~2 days), these patients might benefit from serologic tests that can be done quickly in the place where the patient is receiving care.

Lim et al. [8] reported the discovery of a new, quick serologic test for detecting *S. Typhi*, in which anti-*Salmonella* O9 IgM antibodies are detected, and this test seems to be more rapid and accurate than the Widal agglutination test. Both *S. Typhi* and group D *Salmonella* display similarities in their O9 antigen, which contains a sugar, α -D-tyvelose, that is extremely rare in nature [9]; therefore one cannot dismiss the notion that this test may also be useful for the serodiagnosis of nontyphoid salmonellosis. In this study, we aimed to assess the accuracy of the 1-step, 2-min test (TUBEX; IDL Biotech), compared with that of routine stool culture examination.

Patients and methods. We recruited children from 2 pediatric hospitals in Warsaw, Poland, from April 2000 to January 2002. All consecutive children aged <16 years who were admitted to the hospital for acute diarrhea (defined as ≥ 3 profuse, watery, or mucous stools for >1 day but <5 days in patients who required intravenous rehydration) were eligible for the study (figure 1). Children who had a documented history of salmonellosis in the past, who had primary or secondary immune deficiencies, or who were receiving systemic hormonal treatment were excluded. The control group consisted of children aged <16 years who were admitted for acute diarrhea, but whose stool cultures were negative for *Salmonella* species. Informed consent of parents was obtained in each case, and human experimentation guidelines of the Medical University of Warsaw were followed in the conduct of this clinical research.

For all patients, stool samples were collected at admission and were inoculated onto *Salmonella-Shigella* and McConckey agar (Centralna Pożywkarnia SanEpid) in the laboratory within 2 h of collection. Organisms were identified by standard methods, including triple-sugar iron slants, and were serotyped with commercial serotyping antiserum (Biomed). Patients then were assigned to one of the experimental groups, and their blood

Received 24 June 2002; revised 12 September 2002; electronically published 11 December 2002.

Financial support: Medical University of Warsaw (grant 1W34/W2/00-01 to W.F.).

^a Present affiliation: Dept. of Pediatric Gastroenterology, Hepatology and Nutrition, Children's Memorial Health Institute, Warsaw, Poland (G.O.).

^b G.O. and W.F. contributed equally to this work.

Reprints or correspondence: Dr. Wojciech Feleszko, Dept. of Pediatric Pneumonology, Allergic Diseases, and Hematology, Medical University Children's Hospital, Ul. Działdowska 1, PL-01-184 Warszawa, Poland (wfeleszk@ib.amwaw.edu.pl).

Clinical Infectious Diseases 2003;36:112-5

© 2003 by the Infectious Diseases Society of America. All rights reserved.
1058-4838/2003/3601-0018\$15.00




Figure 1. Study diagram. TUBEX, 1-step, 2-min test (IDL Biotech).

samples (drawn as part of routine laboratory examination) were collected and stored frozen at -20°C until analysis.

The serodiagnosis of infection with *S. Enteritidis* was performed by means of the TUBEX test, which detected anti-*Salmonella* O9 IgM antibodies in the serum, as described elsewhere [8]. In brief, the inhibition of binding between an anti-*Salmonella* O9 IgM monoclonal antibody conjugated to colored latex particles and *S. Typhi* lipopolysaccharide conjugated to magnetic latex particles was measured, and the resultant color of the supernatant was recorded in a blinded fashion by 2 investigators and then was compared with color standards provided by the manufacturer. Next, an appropriate score between 0 and 10 was assigned. A TUBEX score of 4, corresponding to detection of 31 micrograms of the anti-*Salmonella* antibody per milliliter, was arbitrarily taken as the lower limit for a positive reaction [8].

For the evaluation of the results of this study, a contingency table analysis was performed (calculating the 95% CI values) and was computed by Instat 2.0 software (GraphPad Software). $P < .05$ was considered to be statistically significant.

Results. One hundred ninety patients (94 in the study group and 96 in the control group) were enrolled in the study from April 2000 to January 2002 (figure 1). Eighty-seven (92.6%) of 94 children infected with *S. Enteritidis* had a positive

TUBEX result. The positive scores obtained ranged from 4 (23 patients) to 10 (27 patients; figure 2). The median score was 7 (95% CI, 6.82–7.1). In contrast, 91 (94.8%) of 96 control serum samples had a score <4 (a negative TUBEX result), with a median score of 0 (95% CI, 0.2–0.7; figure 2). These patients corresponded in age and sex with those in the examined group. No correlation between antibody concentration (expressed as TUBEX score) and duration of diarrhea in *Salmonella*-infected patients was observed.

The difference in the TUBEX score between *Salmonella*-infected patients and the control subjects was highly significant ($P < .0001$, Mann-Whitney *U* test, 2-tailed). Compared with that of the stool culture, the sensitivity and specificity of the TUBEX test were 92.6% (95% CI, 85.3–97.0) and 94.8% (95% CI, 88.3–98.3), respectively; the positive and negative predictive values were 94.7% (95% CI, 87.7–98.2) and 92.9% (95% CI, 85.8–97.1), respectively. Statistical evaluation of the results revealed that the row/column association was extremely significant ($P < .0001$, Fisher's exact test, 1-sided). The positive likelihood ratio calculated for this test was 17.7, and the negative likelihood ratio was 0.079.

Discussion. In this study of 190 children, the new serologic test was proved to be effective in the serodiagnosis of nontyphoid salmonellosis. This test was primarily designed to di-




Figure 2. Frequency distribution of serum samples obtained from *Salmonella* serotype Enteritidis–infected patients (A) and control subjects (B), according to the new 1-step, 2-min test (TUBEX; IDL Biotech) scores, with linear tendency curve fit.

agnose typhoid fever and reportedly was 100% sensitive and specific in the detection of *S. Typhi* infection [8]; however, in our study, a 92.6% sensitivity and 94.8% specificity for nontyphoid salmonellosis was demonstrated. These results correspond significantly to the results of stool culture. Although microbiological examination of blood or fecal samples remains the “gold standard” laboratory test for the confirmation of salmonellosis, a rapid serologic test based on antibody detection may provide a convenient supplementation. The value of the old serologic diagnosis (with the Widal agglutination test) is often questioned [10], and the most sensitive and specific assay, ELISA, is prohibitively expensive [8, 10]. For these reasons, a sensitive, simple, and cost-effective serologic diagnostic method for the diagnosis of *Salmonella* infection may result not only

in rapid instigation of salmonellosis control measures but also in prompt diagnosis followed by appropriate treatment.

S. Enteritidis remains the most likely bacterial cause of foodborne, acute gastroenteritis in industrialized European countries; the other serotype, group D *Salmonella*, seems to not play any significant role [5, 11]. Only sporadic cases of typhoid fever are registered in the European countries and the United States [11], and no single case of *S. Typhi* was observed in Poland in the past 10 years [5]. Our results highlight the potential of the TUBEX test in the supplementary diagnosis of acute infectious gastroenteritis in these regions; however, its applicability for diagnosis of typhoid fever in these countries is limited. In view of these facts, it seems unlikely that positive results of the test reflected false-positive findings, possibly due to preexisting *S. Typhi* infections. However, the problem of false-positive results due to previous *S. Enteritidis* infections remains to be investigated. In this study, the serodiagnosis of *Salmonella* infection was performed within 3–8 days after the onset of the symptoms, which might positively affect the level of sensitivity of the test. This requires further investigation.

In conclusion, our data highlight the potential of the TUBEX test to supplement existing methods of diagnosis of *Salmonella* infections. TUBEX has been demonstrated to be a rapid, cost-effective, simple, and sensitive method for the diagnosis of *Salmonella* infection, and its positive likelihood ratio in our study was relatively high (17.7). One may speculate that this test also may be applied to individuals with a postinfectious reactive arthritis, for whom stool culture results are often negative [12]. To our knowledge, this report is the first to demonstrate the potent diagnostic value of quick diagnosis of *S. Enteritidis*–derived gastrointestinal infection; however, further studies are warranted for evaluation of the clinical applicability of TUBEX as a novel approach for the diagnosis of *Salmonella* infection.

References

1. Aranda-Michel J, Giannella RA. Acute diarrhea: a practical review [review]. *Am J Med* **1999**;106:670–6.
2. Olsen SJ, Bishop R, Brenner FW, et al. The changing epidemiology of *Salmonella*: trends in serotypes isolated from humans in the United States, 1987–1997. *J Infect Dis* **2001**;183:753–61.
3. Blaser MJ. How safe is our food? Lessons from an outbreak of salmonellosis [editorial]. *N Engl J Med* **1996**;334:1324–5.
4. Mead PS, Slutsker L, Dietz V, et al. Food-related illness and death in the United States [review]. *Emerg Infect Dis* **1999**;5:607–25.
5. Gonera E. Salmonellosis in Poland in 1999. *Przegl Epidemiol* **2001**;55:75–83.
6. Baldassano RN, Cochran WJ. Diarrhea. In: Atschuler SM, Liacouras ChA, eds. *Clinical pediatric gastroenterology*. New York: Churchill Livingstone, **1998**:9–18.
7. Nelson SJ, Granoff D. *Salmonella* gastroenteritis in the first three months of life: a review of management and complications. *Clin Pediatr (Phila)* **1982**;21:709–12.

8. [Lim PL, Tam FC, Cheong YM, Jegathesan M. One-step 2-minute test to detect typhoid-specific antibodies based on particle separation in tubes. J Clin Microbiol 1998;36:2271–8.](#)
9. [Jann K, Westphal O. Microbial polysaccharides. In: Sela M, ed. The antigens. Vol 3. New York: Academic Press, 1975:1–25.](#)
10. [Isomaki O, Vuento R, Granfors K. Serological diagnosis of *Salmonella* infections by enzyme immunoassay. Lancet 1989; 1:1411–4.](#)
11. World Health Organization fact sheet: typhoid fever. Available at: <http://www.who.int/health-topics/typhoid.htm>. Accessed 1 September 2002.
12. [Thomson GT, DeRubeis DA, Hodge MA, Rajanayagam C, Inman RD. Post-*Salmonella* reactive arthritis: late clinical sequelae in a point source cohort. Am J Med 1995;98:13–21.](#)